HIV molecular immunology database

 

Search the Epitope Variant and Escape Mutation Database

Help


Found 2 matching records:

Displaying record number 52308

HXB2 Location  Gag(77-85)   Gag Epitope Map
View variants at this location
Epitope SLYNTVATL   Epitope Alignment
Variants
SLfNTVATL   susceptible form
SLYNTiATL   susceptible form
SLYNTVAvL   susceptible form
Species (MHC/HLA (A*02:01)

Variant Details

Showing all: 3 variant(s).


Variant ID.  3244
Epitope Seq.  SLYNTVATL
Variant Seq.  SLfNTVATL
Mutations Y/F
Epitope Location Y3F
HXB2 Location Y79F
Mutation Type SF: susceptible form
Note SLfNTVATL was a recognized variant.


Variant ID.  3245
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNTiATL
Mutations V/I
Epitope Location V6I
HXB2 Location V82I
Mutation Type SF: susceptible form
Note SLYNTiATL was a recognized variant.


Variant ID.  3246
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNTVAvL
Mutations T/V
Epitope Location T8V
HXB2 Location T84V
Mutation Type SF: susceptible form
Note SLYNTVAvL was a recognized variant.

References

Schoenbach2002 Christian Schönbach, Yu Kun, and Vladimir Brusic. Large-scale Computational Identification of HIV T-Cell Epitopes. Immunol. Cell Biol., 80(3):300-306, Jun 2002. PubMed ID: 12067417. Show all entries for this paper.

Sewell1997 A. K. Sewell, G. C. Harcourt, P. J. Goulder, D. A. Price, and R. E. Phillips. Antagonism of Cytotoxic T Lymphocyte-Mediated Lysis by Natural HIV-1 Altered Peptide Ligands Requires Simultaneous Presentation of Agonist and Antagonist Peptides. Eur. J. Immunol., 27:2323-2329, 1997. PubMed ID: 9341776. Show all entries for this paper.


Displaying record number 85

HXB2 Location  Gag(77-85)   Gag Epitope Map
View variants at this location
Epitope SLYNTVATL   Epitope Alignment
Variants
SLfNTVATL   observed variant
SLfNTVAvL   diminished HLA binding or increased off-rate
SLsNTVATL   diminished HLA binding or increased off-rate
SsfNTVATL   observed variant
SLlNTVATL   diminished HLA binding or increased off-rate
SLcNTVATL   diminished HLA binding or increased off-rate
SLYNTiATL   observed variant
SLfNaVATL   diminished HLA binding or increased off-rate
SLfNTiAvL   diminished HLA binding or increased off-rate
SLfNTiATL   observed variant
SLYNTiAvL   diminished HLA binding or increased off-rate
Epitope Name SL9
Species (MHC/HLA human(A2)

Variant Details

Showing all: 11 variant(s).


Variant ID.  3233
Epitope Seq.  SLYNTVATL
Variant Seq.  SLfNTVATL
Mutations Y/F
Epitope Location Y3F
HXB2 Location Y79F
Mutation Type OV: observed variant
Method Chromium-release assay, HLA binding
Note Natural 3F variant SLfNTVATL, was found in patients 001 and 008. Variant peptide bound HLA-A*02 at a relative binding of 109% compared to SL9 index peptide. Lysis is abrogated in CTL line 9300868 at lower concentrations, but occurs in CTL line 003.


Variant ID.  3234
Epitope Seq.  SLYNTVATL
Variant Seq.  SLfNTVAvL
Mutations Y/F T/V
Epitope Location Y3F T8V
HXB2 Location Y79F T84V
Mutation Type DHB: diminished HLA binding or increased off-rate
Method Chromium-release assay, HLA binding
Note Natural 3F,8V variant SLfNTVAvL, was found in patients 001 and 008. Variant peptide bound HLA-A*02 at a relative binding of 72% compared to SL9 index peptide. Lysis is abrogated in CTL line 9300868 at lower concentrations, but occurs in CTL line 003.


Variant ID.  3235
Epitope Seq.  SLYNTVATL
Variant Seq.  SLsNTVATL
Mutations Y/S
Epitope Location Y3S
HXB2 Location Y79S
Mutation Type DHB: diminished HLA binding or increased off-rate
Method Chromium-release assay, HLA binding
Note Natural 3S variant SLsNTVATL, was found in patient 008. Variant peptide bound HLA-A*02 at a relative binding of 84% compared to SL9 index peptide. Lysis is abrogated in CTL lines 9300868 and 003 at lower concentrations.


Variant ID.  3236
Epitope Seq.  SLYNTVATL
Variant Seq.  SsfNTVATL
Mutations L/S Y/F
Epitope Location L2S Y3F
HXB2 Location L78S Y79F
Mutation Type OV: observed variant
Method Chromium-release assay, HLA binding
Note Natural 2S,3F variant SsfNTVATL, was found in patient 008.


Variant ID.  3237
Epitope Seq.  SLYNTVATL
Variant Seq.  SLlNTVATL
Mutations Y/L
Epitope Location Y3L
HXB2 Location Y79L
Mutation Type DHB: diminished HLA binding or increased off-rate
Method Chromium-release assay, HLA binding
Note Natural 3L variant SLlNTVATL, was found in patients 003 and 008. Variant peptide bound HLA-A*02 at a relative binding of 76% compared to SL9 index peptide. Lysis is abrogated in CTL lines 9300868 and 003 at lower concentrations.


Variant ID.  3238
Epitope Seq.  SLYNTVATL
Variant Seq.  SLcNTVATL
Mutations Y/C
Epitope Location Y3C
HXB2 Location Y79C
Mutation Type DHB: diminished HLA binding or increased off-rate
Method Chromium-release assay, HLA binding
Note Variant peptide SLcNTVATL bound HLA-A*02 at a relative binding of 86% compared to SL9 index peptide. Lysis is abrogated in CTL lines 9300868 and 003 at lower concentrations.


Variant ID.  3239
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNTiATL
Mutations V/I
Epitope Location V6I
HXB2 Location V82I
Mutation Type OV: observed variant
Method Chromium-release assay, HLA binding
Note Natural 6I variant SLYNTiATL, was found in patients 9300868 and 241. Variant peptide bound HLA-A*02 at a relative binding of 114% compared to SL9 index peptide. Lysis of CTL lines occurs at all concentrations of peptide tested.


Variant ID.  3240
Epitope Seq.  SLYNTVATL
Variant Seq.  SLfNaVATL
Mutations Y/F T/A
Epitope Location Y3F T5A
HXB2 Location Y79F T81A
Mutation Type DHB: diminished HLA binding or increased off-rate
Method Chromium-release assay, HLA binding
Note 3F, 5A variant peptide SLfNaVATL bound HLA-A*02 at a relative binding of 80% compared to SL9 index peptide, but is a strict antagonist. Lysis is abrogated in CTL lines 9300868 and 003 at all concentrations tested.


Variant ID.  3241
Epitope Seq.  SLYNTVATL
Variant Seq.  SLfNTiAvL
Mutations Y/F V/I T/V
Epitope Location Y3F V6I T8V
HXB2 Location Y79F V82I T84V
Mutation Type DHB: diminished HLA binding or increased off-rate
Method Chromium-release assay, HLA binding
Note 3F, 6I, 8V variant peptide SLfNTiAvL bound HLA-A*02 at a relative binding of 48% compared to SL9 index peptide. Lysis is abrogated in CTL line 9300868 but occurs in CTL line 003.


Variant ID.  3242
Epitope Seq.  SLYNTVATL
Variant Seq.  SLfNTiATL
Mutations Y/F V/I
Epitope Location Y3F V6I
HXB2 Location Y79F V82I
Mutation Type OV: observed variant
Method Chromium-release assay, HLA binding
Note 3F, 6I variant peptide SLfNTiATL bound HLA-A*02 at a relative binding of 100% compared to SL9 index peptide. Lysis occurs in both CTL lines 9300868 and 003.


Variant ID.  3243
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNTiAvL
Mutations V/I T/V
Epitope Location V6I T8V
HXB2 Location V82I T84V
Mutation Type DHB: diminished HLA binding or increased off-rate
Method Chromium-release assay, HLA binding
Note 6I, 8V variant peptide SLYNTiAvL was found in patient 9300868 and bound HLA-A*02 at a relative binding of 58% compared to SL9 index peptide. Lysis occurs in both CTL lines 9300868 and 003.

References

Sewell1997 A. K. Sewell, G. C. Harcourt, P. J. Goulder, D. A. Price, and R. E. Phillips. Antagonism of Cytotoxic T Lymphocyte-Mediated Lysis by Natural HIV-1 Altered Peptide Ligands Requires Simultaneous Presentation of Agonist and Antagonist Peptides. Eur. J. Immunol., 27:2323-2329, 1997. PubMed ID: 9341776. Show all entries for this paper.


Questions or comments? Contact us at immuno@lanl.gov
 
Managed by Triad National Security, LLC for the U.S. Department of Energy’s National Nuclear Security Administration
Copyright © 2022 Triad National Security, LLC | Disclaimer/Privacy

Dept of Health & Human Services Los Alamos National Institutes of Health